The patent, which is the second notice of allowance from the USPTO in recent months, is expected to expire no earlier than October 2030.
The allowed application covers the WaferiX technology and provides specific protection for WaferiX delivering ketamine (Wafermine), which is iX Biopharma’s lead drug under development, which is available for out-licensing.
iX Biopharma says it has filed corresponding patent applications in other key markets around the world.
Shares in iX Biopharma closed 1 cent higher, or 3.7% up, at 28 cents on August 3.
